A study found that PD-L1, PD-L2 and tumor mutation burden from a comprehensive genomic and transcriptomic profiling test independently predicted Keytruda (pembrolizumab) benefit in pan-solid tumors—and when combined in a multivariate signature score—predicted benefit better than PD-L1 or TMB alone.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
